

PATENT
09/162,648
Docket: SEQ-2

REMARKS

The undersigned is grateful to the Examiner for providing him with a replacement copy of the Advisory Action dated September 22, 2004.

The undersigned is also grateful to the Examiner for the courtesy of an interview at the Patent Office on March 2, 2005. The amendments and remarks presented in this paper were discussed.

The Advisory Action indicates that claims 10-11 and 23-32 are in condition for allowance. Claim 20 stands rejected as either not being a novel product, or because it is unclear as to how the information referred to in the claim is contained in the product or administered to the patient.

By way of this amendment, claim 20 has been amended to state explicitly that the claimed product has two components: a pharmaceutical composition made of lymphocytes, designed for administration to a cancer patient; and separate written information that directs the clinician as to the administration of the composition according to the method of claim 23. The composition and the written information are packaged together, so that a clinician purchasing the product will be directed to administer the product in accordance with the method. This is supported in the specification as filed in the penultimate paragraph before the Example section.

Since the method of claim 23 has been determined to be new and enabled by the disclosure, and since claim 23 is a method for using the composition which is the first component of the product of claim 20, then instructions to use the composition is according to claim 23 is also new. Thus, the combined product of the pharmaceutical composition and the written information is new and enabled, and complies with all the requirements for patentability.

Applicant respectfully submits that claim 20 as amended is allowable, and hence, the entire application is in condition for allowance.


BEST AVAILABLE COPY

PATENT
09/162,648
Docket: SEQ-2

Accompanying this paper is a request for a five month time extension.

Should the Patent Office determine that a further extension of time or other relief is required for further consideration of this application, applicant hereby petitions for such relief and authorizes the Commissioner to charge the cost of such petitions and other fees due in connection with the filing of this paper to Deposit Account 50-3320.

Respectfully submitted,


J. Michael Schiff
Registration No. 40,253

Meyer Pharmaceuticals LLC
1761 Kaiser Avenue
Irvine, CA 92616
Phone: 650-327-0960

March 11, 2005

BEST AVAILABLE COPY